ANDAs Must Show Inactive Ingredient Changes Do Not Affect Efficacy - FDA
Executive Summary
Applications for generic drug products with different inactive ingredients than the innovator drug must demonstrate that efficacy is unaffected, FDA said in its proposed rule revising the regulation on bioequivalence/bioavailability and the content and format of abbreviated new drug applications.
You may also be interested in...
Bioequivalence Final Rule Requires “Appropriate” Sampling For ANDA Tests
FDA's final rule on bioavailability and bioequivalence for ANDAs requires "appropriate" sampling to establish a drug's steady state instead of sampling on three consecutive days as outlined in the proposed rule
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials